A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress and reported March 13 by Healio.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
